CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo

Molecular and Cellular Biochemistry

Volumn 316, Issue 1-2, 2008, Pages 163-167

  Perea, Silvio E ^a   Reyes, Osvaldo ^a   Baladron, Idania ^a   Perera, Yasser ^a   Farina, Hernán ^g   Gil, Jeovanis ^a   Rodriguez, Arielis ^a   Bacardi, Dania ^a   Marcelo, Jose L ^a   Cosme, Karelia ^a   Cruz, Marisol ^a   Valenzuela, Carmen ^a   López Saura, Pedro A ^a   Puchades, Yaquelin ^a   Serrano, Joem M ^a   Mendoza, Osmani ^a   Castellanos, Lila ^a   Sanchez, Aniel ^a   Betancourt, Lazaro ^a   Besada, Vladimir ^a   Silva, Ricardo ^a   López, Ernesto ^a   Falcón, Viviana ^a   Hernández, Ignacio ^a   Solares, Margarita ^b   Santana, Agueda ^c   Díaz, Alina ^e   Ramos, Thelvia ^a   López, Carlos ^e   Ariosa, Juan ^d   González, Luis J ^a   Garay, Hilda ^a   Gómez, Daniel ^g   Gómez, Roberto ^f   Alonso, Daniel F ^g   Sigman, Hugo ^f   Herrera, Luis ^a   Acevedo, Boris ^a   more..

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Gyneco obstetric Hospital Clodomira Acosta Ferrales   (Cuba)

^c Gyneco obstetric Hospital 10 de Octubre   (Cuba)

^d HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^e National Center for Toxicology   (Cuba)

^f ELEA Laboratories   (Argentina)

^g UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Apoptosis; Cancer targeted therapy; Casein kinase 2

Indexed keywords

ANTINEOPLASTIC AGENT; CASEIN KINASE II; CASPASE; CIGB 300;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING SITE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FACE EDEMA; FEMALE; HOT FLUSH; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE PAIN; INJECTION SITE REACTION; MOUSE; MUSCLE CRAMP; NONHUMAN; NUDE MOUSE; PHAGE DISPLAY; PROTEIN PHOSPHORYLATION; PRURITUS; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL ASSAY; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; ONCOGENE PROTEINS, VIRAL; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROTEOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 50649097687     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9814-5     Document Type: Article

References (17)

1. Baselga J (2006) Targeting tyrosine kinases in cancer. Science 312:1175-1178. doi: 10.1126/science.1125951
2. Kantarjian HM, Cortes J (2006) New strategies in chronic myeloid leukemia. Int J Hematol 83:289-293. doi: 10.1532/IJH97.06024
3. Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349-368. doi: 10.1096/fj.02-0473rev
4. Johnston IM, Allison SJ, Morton JP, Schramm L, Scott P, White RJ (2002) CK2 forms a stable complex with TFIIIB and activates RNA polymerase III transcription in human cells. Mol Cell Biol 22:3757-3768. doi: 10.1128/ MCB.22.11.3757-3768.2002
5. Guerra B, Issinger O-G (1999) Protein kinase CK2 and its role in cellular proliferation, development, and pathology. Electrophoresis 20:391-408. doi:10.1002/ (SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N
6. Ahmed K, Gerber DA, Cochet C (2002) Joining the cell survival squad: An emerging role for protein kinase CK2. Trends Cell Biol 12:226-230. doi: 10.1016/S0962-8924(02)02279-1
7. Barz T, Ackermann K, Dubois G, Eils R, Pyerin W (2003) Genome-wide expression screens indicate a global role for protein kinase CK2 in chromatin remodeling. J Cell Sci 116:1563-1577. doi: 10.1242/jcs.00352
8. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al (2006) Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108:1698-1707. doi: 10.1182/blood-2005-11-013672
9. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC (1998) P53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice. Oncogene 16:2965-2974. doi: 10.1038/sj.onc.1201854
10. Landesman-Bollag E, Song DH, Romieu-Mourez R, Sussman DJ, Cardiff RD, Sonenshein GE et al (2001) Protein kinase CK2: Signaling and tumorigenesis in the mammary gland. Mol Cell Biochem 227:153-165. doi: 10.1023/A:1013108822847
11. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K (2001) Protein kinase CK2 signal in neoplasia. Histol Histopathol 16:573-582
12. Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K (1996) Elevated protein kinase CK2 activity in chromatin of head and neck tumors: Association with malignant transformation. Cancer Lett 101:31-35. doi: 10.1016/0304-3835(96)04110-9
13. Serno S, Salvi M, Battistutta R, Zanotti G, Pinna LA (2005) Features and potentials of ATP-site directed CK2 inhibitors. Biochim Biophys Acta 1754:263-270
14. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K (2004) Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2:712-720
15. Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I et al (2004) Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the Casein Kinase 2 (CK2). Cancer Res 64:7127-7129. doi: 10.1158/0008-5472.CAN-04-2086
16. Fields R (1990) Nobel, Solid phase peptide synthesis utilizing 9-fluorenylmethoxycabonyl amino acid. Int J Pept Protein Res 35:161-214
17. Perera Y, Farina HG, Hernández I, Mendoza O, Serrano JM, Reyes O et al (2008) Systemic administration of a peptide that impairs the Protein Kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int J Cancer 122:57-62. doi: 10.1002/ijc.23013